Article | October 30, 2024

Navigating Government Investigations: A Guide for FDA-Regulated Companies

Read More

Article | October 29, 2024

Responding to Letters from FDA

Read More

Article | October 23, 2024

OIG’s Perspective on Discount and Refund Programs

Read More

Article | October 21, 2024

What the DOJ Looks For: Key Insights into Evaluating Your Compliance Program

Read More

Article | October 15, 2024

FDA Compliance: Conducting a Recall

Read More

Article | October 10, 2024

Gardner Law Launches Litigation Practice with Renowned Attorney David Graham

Read More

Article | October 01, 2024

Latest Untitled Letter from FDA’s OPDP Underscores Need for Careful Approach to Advertising

Read More

Article | September 25, 2024

Hiring Conflicts Result in FCA Violations

Read More

Article | September 18, 2024

Privacy Summer School – “Back to School” Recap

Read More

Article | September 05, 2024

Navigating the Biosecure Act: Implications for Biotechnology and Pharmaceutical Companies

Read More

Article | September 04, 2024

DOJ Launches New Whistleblower Incentive Program

Read More

Article | August 29, 2024

Avoiding Post-Approval FDA Scrutiny: Drug Marketing Materials

Read More